sucroferric oxyhydroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5121 8047-67-4

Description:

MoleculeDescription

Synonyms:

  • ferric oxyhydroxide
  • sucroferric oxyhydroxide
  • velphoro
  • ferric oxide saccharated
  • saccharated iron oxide
an oral phosphate binder for treatment of hyperphosphatemia
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.11 g O
1.50 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 2013 FDA VIFOR FRESENIUS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 418.07 52.26 159 655 374222 63113986
Shunt stenosis 123.75 52.26 18 796 522 63487686
Shunt occlusion 82.40 52.26 13 801 652 63487556
Product taste abnormal 73.92 52.26 14 800 2053 63486155
Diarrhoea 71.42 52.26 64 750 715302 62772906

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 618.40 37.90 310 1276 397739 34557606
Shunt stenosis 172.52 37.90 30 1556 752 34954593
Haemoglobin increased 133.77 37.90 31 1555 3378 34951967
Faeces discoloured 116.28 37.90 38 1548 14840 34940505
Shunt occlusion 86.24 37.90 17 1569 853 34954492
Diarrhoea 82.58 37.90 94 1492 389818 34565527
Product taste abnormal 69.73 37.90 15 1571 1159 34954186
Transferrin saturation increased 44.00 37.90 7 1579 99 34955246
Haematocrit increased 41.30 37.90 11 1575 2102 34953243
Serum ferritin increased 41.17 37.90 14 1572 6132 34949213
Tooth discolouration 40.21 37.90 8 1578 420 34954925

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Shunt stenosis 312.22 33.19 48 1492 1343 79741505
Shunt occlusion 178.53 33.19 30 1510 1474 79741374
Haemoglobin increased 153.26 33.19 33 1507 6099 79736749
Serum ferritin increased 78.12 33.19 21 1519 9826 79733022
Transferrin saturation increased 72.26 33.19 10 1530 129 79742719
Diarrhoea 68.68 33.19 84 1456 880405 78862443
Product taste abnormal 61.09 33.19 13 1527 2258 79740590
Peripheral arterial occlusive disease 57.98 33.19 16 1524 8242 79734606
Haematocrit increased 53.66 33.19 13 1527 4021 79738827
Hyperparathyroidism secondary 53.54 33.19 12 1528 2648 79740200
Faeces discoloured 52.11 33.19 20 1520 29107 79713741

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B03AB02 BLOOD AND BLOOD FORMING ORGANS
ANTIANEMIC PREPARATIONS
IRON PREPARATIONS
Iron trivalent, oral preparations
ATC V03AE05 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA N0000020074 Phosphate Chelating Activity
FDA EPC N0000175597 Phosphate Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperphosphatemia indication 20165001 DOID:0050459




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 500MG IRON VELPHORO VIFOR FRESENIUS N205109 Nov. 27, 2013 RX TABLET, CHEWABLE ORAL 9561251 Jan. 23, 2030 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
20344-49-4 SECONDARY_CAS_RN
D04616 KEGG_DRUG
4021278 VANDF
4033084 VANDF
C3696416 UMLSCUI
CHEBI:192761 CHEBI
CHEMBL3039566 ChEMBL_ID
DB09146 DRUGBANK_ID
CHEMBL4802224 ChEMBL_ID
CHEMBL1200823 ChEMBL_ID
C000599459 MESH_SUPPLEMENTAL_RECORD_UI
C092844 MESH_SUPPLEMENTAL_RECORD_UI
DB14695 DRUGBANK_ID
1484283 RXNORM
15814 MMSL
221324 MMSL
30331 MMSL
30334 MMSL
d04725 MMSL
d08266 MMSL
007471 NDDF
008975 NDDF
015366 NDDF
1285045009 SNOMEDCT_US
129497004 SNOMEDCT_US
387206004 SNOMEDCT_US
421953007 SNOMEDCT_US
737661000168109 SNOMEDCT_US
9793696 PUBCHEM_CID
87PZU03K0K UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Velphoro HUMAN PRESCRIPTION DRUG LABEL 1 49230-645 TABLET, CHEWABLE 500 mg ORAL NDA 26 sections
Velphoro HUMAN PRESCRIPTION DRUG LABEL 1 49230-645 TABLET, CHEWABLE 500 mg ORAL NDA 26 sections